During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
- Treating nasty cancer side effectson November 18, 2019 at 7:42 pm
WASHINGTON – Overall, cancer deaths in the United States have gone down for the past two decades, thanks in part to immunotherapy and specialized therapies. But those life-saving treatments sometimes ...
- How gene-edited white blood cells are helping fight canceron November 18, 2019 at 4:14 pm
To develop a safer and more effective treatment for cancer patients, scientists from the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy in San Francisco and Tmunity ...
- Why Hasn’t Immunotherapy Been Working For Prostate Cancer? Bone Tumors May Be The Answeron November 18, 2019 at 4:00 pm
Researchers from MD Anderson in Texas have uncovered new clues as to why immunotherapy may fail in ... [+] many men with prostate cancer. Immunotherapy drugs called immune checkpoint inhibitors have ...
- Dr. Martin 'Mac' Cheever, cancer immunotherapy expert, receives distinguished service awardon November 15, 2019 at 1:32 pm
Cancer immunotherapy expert Dr. Martin ‘Mac’ Cheever of Fred Hutchinson Cancer Research Center on Nov. 9 was awarded the first-ever Distinguished Service Award from the Society for the Immunotherapy ...
- Prostate cancer bone metastases thwart immunotherapy by producing TGF-betaon November 14, 2019 at 8:07 am
The discoveries by a team led by Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at MD Anderson, explain why immunotherapy has been largely unsuccessful ...
- Cancer Immunotherapy Market Global Outlook by Size, Share, Trend, Growth, Demand, Industry Analysis, Business Strategies by 2023on November 13, 2019 at 5:28 pm
Amgen Inc., Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc. Get Exclusive Free Sample Copy @ ...
- Rheumatoid Arthritis Is No Bar to Cancer Immunotherapyon November 13, 2019 at 1:17 pm
Some cancer cells exploit these molecules to dial down immune attacks that would otherwise ... The 22-patient cohort was about age 67 on average and, as is typical of RA, three-quarters were women. RA ...
- Gene Modifying Immunotherapy for Blood Cancer Market to Expand on Account of Rising Research and Development Activities By 2027on November 13, 2019 at 2:36 am
Research Nester released a report titled “Gene Modifying Immunotherapy for Blood Cancer Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global gene ...
- Regular screening, immunotherapy among latest weapons against lung canceron November 12, 2019 at 2:00 pm
The chances of remission and recovery decline in later stage cancer, making the low-dose CT scan even more important. * I understand and agree that registration on or use of this site constitutes ...
- Cancer Immunotherapy Market 2019 Global Industry Overview Growth By 2024 – Market Research Engineon November 12, 2019 at 4:51 am
Nov 12, 2019 (Heraldkeepers) -- New York, November 12, 2019: The cancer immunotherapy market is segmented on the lines of its type, application, end user and regional. Based on type segmentation it ...
via Google News and Bing News